Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
2.260
-0.220 (-8.87%)
At close: Nov 4, 2024, 4:00 PM
2.320
+0.060 (2.65%)
After-hours: Nov 4, 2024, 6:11 PM EST
Werewolf Therapeutics Employees
Werewolf Therapeutics had 47 employees as of December 31, 2023. The number of employees increased by 1 or 2.17% compared to the previous year.
Employees
47
Change (1Y)
1
Growth (1Y)
2.17%
Revenue / Employee
$197,511
Profits / Employee
-$1,143,191
Market Cap
98.77M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 47 | 1 | 2.17% |
Dec 31, 2022 | 46 | 7 | 17.95% |
Dec 31, 2021 | 39 | 15 | 62.50% |
Dec 31, 2020 | 24 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Quantum-Si incorporated | 159 |
AlloVir | 112 |
Invivyd | 95 |
Immunic | 77 |
Assembly Biosciences | 65 |
Elutia | 54 |
Sensus Healthcare | 35 |
Genelux | 23 |
HOWL News
- 4 weeks ago - Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1 - Seeking Alpha
- 4 months ago - Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma - GlobeNewsWire
- 5 months ago - Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors - GlobeNewsWire
- 5 months ago - Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting - GlobeNewsWire
- 6 months ago - Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire